DT&CRO CO., Ltd. (KOSDAQ:383930)

Market Cap	32.66B -39.2%
Revenue (ttm)	47.77B +20.9%
Net Income	-12.28B
EPS	-1,202.77
Shares Out	12.78M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	153,247
Open	2,625.00
Previous Close	2,700.00
Day's Range	2,430.00 - 2,675.00
52-Week Range	2,250.00 - 4,780.00
Beta	1.10
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About DT&CRO CO.

DT&CRO CO., Ltd. operates as a full-service CRO provider in South Korea. The company conducts a series of consigned studies ranging from non-clinical GLP toxicity, PK, and efficacy tests required for licensing of pharmaceuticals, chemicals, health functional food, cosmetics, and medical devices to analysis, bioactivity, clinical trials, and licensing consulting. DT&CRO CO., Ltd. was founded in 2017 and is based in Yongin-si, South Korea.

• Industry: Commercial Physical and Biological Research
• Founded: 2017
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 383930

Financial Performance

In 2025, DT&CRO CO.'s revenue was 47.75 billion, an increase of 32.74% compared to the previous year's 35.97 billion. Losses were -2.78 billion, 38.9% more than in 2024.